Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung CancerAlice T. Shaw, Pasi A. Jänne, Dong‐Wan Kim et al.|New England Journal of Medicine|2013Cited by 3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialTony Mok, Nelly Cherciu, Oscar Avendaño et al.|The Lancet|2019Cited by 3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung CancerTony Mok, Vassiliki A. Papadimitrakopoulou, Yi‐Long Wu et al.|New England Journal of Medicine|2016Cited by 3.3k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Denis Soulières et al.|The Lancet|2018Cited by 1.7k
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trialsAlexander Drilon, Robert C. Doebele, Salvatore Siena et al.|The Lancet Oncology|2019Cited by 537